Quality key factors
Factor
Value
Sales Growth (5y)
-16.80%
EBIT Growth (5y)
-314.18%
EBIT to Interest (avg)
-94.40
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.10
Sales to Capital Employed (avg)
0.02
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
96.78%
ROCE (avg)
0
ROE (avg)
0
Valuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.46
EV to EBIT
-0.27
EV to EBITDA
-0.28
EV to Capital Employed
-3.50
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-124.05%
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Bullish
Technical Movement
5What is working for the Company
NET PROFIT(HY)
Higher at USD -58.76 MM
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
EPS(Q)
Highest at USD -0.6
-7What is not working for the Company
NET PROFIT(HY)
At USD -58.76 MM has Grown at -36.9%
Here's what is working for Lexeo Therapeutics, Inc.
Net Profit
Higher at USD -58.76 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
EPS
Highest at USD -0.6
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Lexeo Therapeutics, Inc.
Net Profit
At USD -58.76 MM has Grown at -36.9%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)






